RecruitingNCT04486638

Dengvaxia US Pregnancy Registry

Dengvaxia US Pregnancy Registry: A Surveillance Study to Assess the Safety of Dengvaxia Among Exposed Pregnant Women and Their Offsprings (DNG00044)

Sponsor

Sanofi Pasteur, a Sanofi Company

Enrollment

500 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Dengue Virus Infection

Summary

The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Dengue Tetravalent Vaccine, Live for people with dengue virus infection. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALDengue Tetravalent Vaccine, Live

Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous

Locations(1)

Investigational Site

San Juan, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04486638